Breathe Well Live Well
|
FDA approves Boehringer's asthma treatment
Westfair Online Asthma, which affects more than 22 million people in the U.S., can cause a patient's airways to become inflamed and tighten, making it hard to breathe, according to Boehringer. One survey found 55 percent of people with asthma taking at least one … |
View full post on asthma – Google News
|
Canada Approves Breo Ellipta for Adults With Asthma
Medscape Canadian regulators have approved the dry powder combination of fluticasone furoate and vilanterol (Breo Ellipta, GlaxoSmithKline/Theravance) for once-a-day treatment of asthma in adults with reversible obstructive airways disease, GlaxoSmithKline … |
View full post on asthma – Google News
Fox News |
FDA approves Glaxo, Theravance's Breo Ellipta asthma drug
Fox News The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said. The FDA declined to approve Breo for younger asthma … GlaxoSmithKline And Theravance: The Asthma Approval In Figures GlaxoSmithKline plc (ADR) Gets FDA Approval For Breo Ellipta To Treat Asthma … FDA Okays Breo Ellipta for Asthma in Adults |
View full post on asthma – Google News
Reuters |
US FDA approves Glaxo, Theravance's Breo Ellipta asthma drug
Reuters (Reuters) – The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said. The FDA declined to approve Breo for younger … GlaxoSmithKline plc (ADR) Gets FDA Approval For Breo Ellipta To Treat Asthma … FDA Okays Breo Ellipta for Asthma in Adults Glaxo Wins U.S. Approval to Sell Breo Only to Adults With Asthma |
View full post on asthma – Google News
Reuters |
FDA approves Glaxo, Theravance's Breo Ellipta asthma drug
Reuters (Reuters) – The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said. The FDA declined to approve Breo for younger … Glaxo Wins U.S. Approval to Sell Breo Only to Adults With Asthma FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US FDA Okays Breo Ellipta for Asthma in Adults |
View full post on asthma – Google News
|
FDA approves GSK's Arnuity Ellipta to treat asthma in US
Pharmaceutical Business Review The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (GSK) fluticasone furoate inhalation powder, to be sold as Arnuity Ellipta, as a daily-once corticosteroid for treatment of asthma in patients aged above twelve years in the US. |
View full post on asthma – Google News
|
FDA approves GlaxoSmithKline's Arnuity Ellipta for treatment of asthma
News-Medical.net GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 … |
View full post on asthma – Google News
|
FDA approves GSK asthma medicine
Philadelphia Business Journal (blog) The product, Arnuity Ellipta, is an inhaled corticosteroid medicine designed to be taken a once-daily by asthma patients 12 years of age and older. Asthma is a chronic lung disease that inflames and narrows the airways. An estimated 26 million people … GlaxoSmithKline plc (GSK) Receives FDA Approval of Arnuity Ellipta as Asthma … GSK Gets FDA Approval For Asthma Drug Arnuity Ellipta |
View full post on asthma – Google News
SeniorJournal.com |
FDA approves Striverdi Respimat for COPD, includes asthma warning
Healio “The safety and effectiveness of Striverdi Respimat in people with asthma has not been established, and it is not approved to treat asthma,” the release said. “Striverdi Respimat should not be used as a rescue therapy to treat sudden breathing problems … FDA Clears Olodaterol (Striverdi Respimat) for COPD Once-Daily Inhaler Approved for COPD FDA approves Boehringer's once-a-day inhaler drug |
View full post on asthma – Google News
|
FDA approves Teva's QVAR with dose counter to treat asthma
Pharmaceutical Business Review The US Food and Drug Administration (FDA) has approved the use of Teva Pharmaceutical's QVAR (beclomethasone dipropionate HFA) with a dose counter for the ongoing treatment of asthma as a preventative therapy in patients five years of age and older. |
View full post on asthma – Google News